Stereotaxis faces a critical juncture as it attempts to scale the Genesis robotic platform amidst significant revenue volatility and persistent operating deficits. While the company maintains a modest debt-to-equity ratio of 0.29, the ongoing reliance on exter...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.05+0.0% vs -$0.05 | $8M-8.1% vs $8M |
Q2 2026 May 12, 2026 | -$0.03+25.0% vs -$0.04 | $6M-26.0% vs $9M |
Q2 2026 Mar 9, 2026 | -$0.06+0.0% vs -$0.06 | $9M-4.8% vs $9M |
Q4 2025 Nov 11, 2025 | -$0.03+50.0% vs -$0.06 | $7M-10.9% vs $8M |
New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.
ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged in Hungary has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system, just over a month after launching its robotic cardiology program.
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
Benchmark STXS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stereotaxis, Inc. (STXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.32 | $129.27M | -5.28 | 20.28% | -66.85% | -143.55% | — | |
| $398.30 | $140.71B | 50.61 | 20.51% | 28.45% | 17.71% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $103.53 | $180.32B | 27.83 | 5.67% | 13.91% | 12.09% | — | |
| $44.62 | $66.32B | 23.00 | 19.87% | 17.47% | 14.76% | — | |
| $89.30 | $114.65B | 23.94 | 8.43% | 13.93% | 10.51% | — |
Stereotaxis, Inc. (STXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Stereotaxis, Inc. (STXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 16, 2026·SEC
Jul 9, 2026·SEC
Get notified when STXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stereotaxis, Inc. (STXS) stock FAQ — growth, dividends, profitability & financials explained
Stereotaxis, Inc. (STXS) reported $30.1M in revenue for fiscal year 2025. This represents a 158985% increase from $0.0M in 2002.
Stereotaxis, Inc. (STXS) grew revenue by 20.3% over the past year. This is strong growth.
Stereotaxis, Inc. (STXS) reported a net loss of $22.3M for fiscal year 2025.
Stereotaxis, Inc. (STXS) has a return on equity (ROE) of -143.6%. Negative ROE indicates the company is unprofitable.
Stereotaxis, Inc. (STXS) had negative free cash flow of $15.5M in fiscal year 2025, likely due to heavy capital investments.
